Ann Tong, MD
Cardiovascular Disease · Gainesville, FLNPI 1902879323
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,551 of the $160,360 with a category attached, or 69.6%. E.r. Squibb & Sons, L.L.C. accounts for 81.6% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $39,079, 3.3 times the $11,710 reported in 2019. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 411 payments — averaging $390.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$131K
- Bayer$14K
- Novartis$11K
- Alnylam Pharmaceuticals Inc.$849
- Amgen$494
- Boehringer Ingelheim$423
- plus $3K from 28 others
Across 20 payments — averaging $2926.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$38K
- Boston Scientific$15K
- Abbott$5K
What the payments were for
- Consulting fees$22,86314%
- Speaking & faculty fees$111,55170%
- Travel & lodging$16,53310%
- Food & beverage$9,3846%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 158 | $130,898 |
| Bayer | 21 | $13,520 |
| Novartis | 36 | $11,089 |
| Alnylam Pharmaceuticals Inc. | 57 | $849 |
| Amgen | 21 | $494 |
| Boehringer Ingelheim | 15 | $423 |
| Pfizer | 20 | $343 |
| Merck | 17 | $294 |
| Sanofi-aventis U.S. LLC | 8 | $206 |
| Boston Scientific | 4 | $198 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $177 |
| Lexicon Pharmaceuticals, Inc. | 9 | $155 |
| Johnson & Johnson | 8 | $152 |
| Recor Medical Inc | 1 | $149 |
| Limflow Inc. | 1 | $135 |
| Stryker | 1 | $134 |
| Cvrx, Inc. | 1 | $124 |
| Esperion Therapeutics, Inc. | 2 | $122 |
| Cook Medical LLC | 1 | $118 |
| Edwards Lifesciences | 1 | $116 |
| Novo Nordisk | 1 | $112 |
| Abiomed | 1 | $110 |
| Abbott | 1 | $82 |
| AstraZeneca | 5 | $79 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $46 |
| Bridgebio Pharma, Inc. | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $35 |
| Bardy Diagnostics, Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $22 |
| Medtronic | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Neuros Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$100,011
- Kerendia$13,230
- ENTRESTO$10,669
- LIMFLOW SYSTEM$269
- Paradise Ultrasound Renal Denervation System$149
- AMVUTTRA$134
- Repatha$125
- Barostim Neo System$124
- PRALUENT$120
- Zilver PTX$118
- Edwards SAPIEN 3 Transcatheter Heart Valve$116
- Ozempic$112
- JARDIANCE$111
- Impella$110
- RESONATE EL ICD VR$107
- NEXLIZET$102
- NEXLETOL$102
How this compares
$160,360 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 364 | $341,328 |
| CamzyosMavacamten | 38 | $300,602 |
| EntrestoSacubitril/Valsartan | 230 | $225,037 |
| JardianceEmpagliflozin | 269 | $219,274 |
| XareltoRivaroxaban | 77 | $72,710 |
| FarxigaDapagliflozin Propanediol | 75 | $57,299 |
| Repatha SureclickEvolocumab | 67 | $48,672 |
| Repatha PushtronexEvolocumab | 25 | $18,357 |
| Praluent PenAlirocumab | 28 | $14,092 |
| MultaqDronedarone Hcl | 12 | $12,275 |
| VascepaIcosapent Ethyl | 15 | $8,768 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 24 | $7,784 |
| Metoprolol Succinate | 576 | $7,255 |
| VerquvoVericiguat | 11 | $7,176 |
| CorlanorIvabradine Hcl | 15 | $5,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $343 | $341,328364 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $130,898 | $300,60238 claims |
| NovartisEntresto | $11,089 | $225,037230 claims |
| Boehringer IngelheimJardiance | $423 | $219,274269 claims |
| Johnson & JohnsonXarelto | $152 | $72,71077 claims |
| AstraZenecaFarxiga | $79 | $57,29975 claims |
| Sanofi-aventis U.S. LLCMultaq | $206 | $12,27512 claims |
| MerckVerquvo | $294 | $7,17611 claims |
| AmgenCorlanor | $494 | $5,14315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Gainesville
- Juan ArandaGainesville$212K
- Keith MarchGainesville$176K
- Carlos Alviar RestrepoGainesville$104K
- Michael KorenGainesville$97K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.